NextCure(NXTC) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Next@ure NextCure Provides Business Update and Reports Third Quarter 2024 Financial Results – Prioritize and focus resources on LNCB74 (B7-H4 ADC) with a planned IND submission by year-end – Cash of approximately $75 million expected to fund operations into second half of 2026 BELTSVILLE, Md. – November 7, 2024 – NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class, and best-in-class therapies to treat cancer, to ...